GlobeNewswire: Syneos Health, Inc. Contains the last 10 of 303 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:02:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/01/09/2806116/0/en/Syneos-Health-Releases-2024-Dealmakers-Intentions-Survey.html?f=22&fvtc=4&fvtv=24062Syneos Health Releases 2024 Dealmakers' Intentions Survey2024-01-09T12:00:00Z<![CDATA[Survey Shows Increased Dealmaking Focus on Antibody-Drug Conjugates, Generative AI Products and Cell & Gene Therapies Survey Shows Increased Dealmaking Focus on Antibody-Drug Conjugates, Generative AI Products and Cell & Gene Therapies]]>https://www.globenewswire.com/news-release/2023/12/20/2799597/0/en/Syneos-Health-Releases-2024-Health-Trends.html?f=22&fvtc=4&fvtv=24062Syneos Health Releases 2024 Health Trends2023-12-20T18:25:39Z<![CDATA[Generative AI Poised to Reinvent Life Sciences, Leading to Profound Changes in Healthcare Generative AI Poised to Reinvent Life Sciences, Leading to Profound Changes in Healthcare]]>https://www.globenewswire.com/news-release/2023/10/03/2753595/0/en/Syneos-Health-Appoints-Colin-Shannon-as-Chief-Executive-Officer.html?f=22&fvtc=4&fvtv=24062Syneos Health Appoints Colin Shannon as Chief Executive Officer2023-10-03T12:00:46Z<![CDATA[Industry Veteran Brings Decades of Experience Driving Growth at Global Biopharmaceutical Solutions Organizations Industry Veteran Brings Decades of Experience Driving Growth at Global Biopharmaceutical Solutions Organizations]]>https://www.globenewswire.com/news-release/2023/09/28/2751390/0/en/Syneos-Health-Closes-Transaction-with-Private-Investment-Firms.html?f=22&fvtc=4&fvtv=24062Syneos Health Closes Transaction with Private Investment Firms2023-09-28T14:24:44Z<![CDATA[Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers]]>https://www.globenewswire.com/news-release/2023/09/26/2749372/0/en/Syneos-Health-Names-Terttu-Haring-President-Clinical-Sites-Patients.html?f=22&fvtc=4&fvtv=24062Syneos Health Names Terttu Haring President, Clinical Sites & Patients2023-09-26T11:30:00Z<![CDATA[Industry Veteran to Play Critical Role in Leading Global Clinical Operations, Cultivating Site Relationships, Empowering Patients and Shaping Innovative Clinical Trial Solutions Industry Veteran to Play Critical Role in Leading Global Clinical Operations, Cultivating Site Relationships, Empowering Patients and Shaping Innovative Clinical Trial Solutions]]>https://www.globenewswire.com/news-release/2023/09/12/2741520/0/en/Syneos-Health-and-Oracle-to-Expand-Relationship-to-Accelerate-Patient-Recruitment-Advance-Health-Equity.html?f=22&fvtc=4&fvtv=24062Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity2023-09-12T11:30:00Z<![CDATA[MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle’s suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient populations participating in medical research.]]>https://www.globenewswire.com/news-release/2023/09/06/2738291/0/en/Syneos-Health-Inc-and-Star-Parent-Inc-Announce-Proposed-1-70-Billion-Offering-of-Senior-Secured-Notes.html?f=22&fvtc=4&fvtv=24062Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured Notes2023-09-06T11:54:49Z<![CDATA[MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”). The Issuer intends to use the proceeds from the offering together with other financing sources to fund the previously announced acquisition of Syneos Health (the “Acquisition”) by the Issuer and certain of its affiliated entities (such affiliates, together with the Issuer, the “Purchasing Entities”) and related refinancings. The Purchasing Entities were newly-formed entities established by a consortium of private investment funds led by Elliott Investment Management L.P. and its affiliates, Patient Square Capital, LP and its affiliates and Veritas Capital Fund Management, L.L.C. and its affiliates. If the sale of the Notes is not completed concurrently with the closing of the Acquisition, then the proceeds from the sale of the Notes will be placed into escrow until the closing of the Acquisition.]]>https://www.globenewswire.com/news-release/2023/08/02/2716877/0/en/Syneos-Health-Stockholders-Approve-Agreement-with-Private-Investment-Consortium.html?f=22&fvtc=4&fvtv=24062Syneos Health Stockholders Approve Agreement with Private Investment Consortium2023-08-02T12:47:45Z<![CDATA[MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company’s stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing of the transaction, if completed.]]>https://www.globenewswire.com/news-release/2023/07/10/2701675/0/en/Syneos-Health-Appoints-Hillary-Bochniak-as-Chief-Human-Resources-Officer.html?f=22&fvtc=4&fvtv=24062Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer2023-07-10T11:30:00Z<![CDATA[Human Resources Leader with Nearly 30 Years of Experience and Commitment to Professional Services Environment Human Resources Leader with Nearly 30 Years of Experience and Commitment to Professional Services Environment]]>https://www.globenewswire.com/news-release/2023/06/26/2694341/0/en/Syneos-Health-and-uMotif-Partner-to-Deliver-Patient-centric-eClinical-Platform.html?f=22&fvtc=4&fvtv=24062Syneos Health and uMotif Partner to Deliver Patient-centric eClinical Platform2023-06-26T11:30:00Z<![CDATA[Integrated eCOA & ePRO Solution Taps Company’s Decentralized Capabilities and Technology Expertise Integrated eCOA & ePRO Solution Taps Company’s Decentralized Capabilities and Technology Expertise]]>